NFKB1 and primary cutaneous T-cell non-Hodgkin lymphoma: Therapies targeting the PI3K pathway (duvelisib), NF-κB inhibitors (bortezomib), alisertib (oral Aurora A kinase inhibitor), or JAK/STAT inhibitors, widely used in inflammatory conditions or hematologic malignancies, may show promise in CTCL and are awaiting efficacy and tolerance results from clinical trials.